Evidence map›Paper›PMID 42169166›Full record

ArticleJournal of cheminformatics2026

ExPO: an exposure-conditioned neural operator for L1000 signature prediction.

Austin Spadaro, Alok Sharma, Iman Dehzangi

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Austin SpadaroCenter for Computational and Integrative Biology, Rutgers University, Camden, NJ, USA.
Alok SharmaInstitute for Integrated and Intelligent Systems, Griffith University, Brisbane, QLD, Australia.
Iman DehzangiCenter for Computational and Integrative Biology, Rutgers University, Camden, NJ, USA. i.dehzangi@rutgers.edu.

Funding

NSF-NRT 2152059
6 · The paper itself

Abstract

Experimental profiling of drug-cell transcriptomic responses over dose and time is sparse and irregular, complicating discovery. We present ExPO, an exposure-conditioned neural operator that predicts full L1000 (978-gene) z-score signatures for a given compound-cell context as a continuous function of exposure. ExPO ifanstantiates a DeepONet, fusing ChemBERTa-2 molecular embeddings (with LoRA adaptation) and a trunk over sinusoidal Fourier features, so signatures can be evaluated at arbitrary dose-time pairs without regridding. Training is discovery-aligned, combining robust regression with a two-list listwise objective to optimize early-rank gene ordering, plus lightweight priors (Sobolev smoothness and an optional dose-monotonicity penalty) for pharmacologic plausibility. On a scaffold-held-out CMap/L1000 benchmark, ExPO improves over strong baselines in both accuracy and ranking (MAE 0.83 vs 0.89, Spearman 0.52 vs 0.48 vs DeepCE; NDCG@50↑/↓ 0.74/0.72 vs 0.71/0.69 for CIGER), tolerates withheld exposures (ΔMAE + 0.03 for interior interpolation; + 0.07 at edges, reduced by - 0.02 with the monotonicity prior), and transfers across cell lines (LCL-O MAE 0.90 vs 0.95; ρ 0.44 vs 0.40). Quantile heads with conformal calibration yield reliable uncertainty (test PICP 0.80/0.90), and filtering the least-confident 20% reduces MAE by ~ 18%. By modeling exposure as a field rather than discrete buckets, ExPO delivers accurate, rank-faithful, and calibrated signatures for in-silico exploration of dose-time surfaces. ExPO as a standalone predictor, along with its source code and benchmark dataset, is available at https://github.com/MLBC-lab/ExPO .

Indexed as

DeepONetDrug–cell transcriptomic responseL1000Neural-operatorSMILES

Identifiers

PMID42169166
PMCPMC13371340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.